Axsome Extends SUNOSI Patent Protection to 2040 in Alkem Settlement

Event summary

  • Axsome Therapeutics settled patent litigation with Alkem Laboratories over SUNOSI (solriamfetol), delaying generic entry until 2040.
  • Alkem can launch a generic version of SUNOSI on or after September 1, 2040, if pediatric exclusivity is granted, or March 1, 2040, if not.
  • The settlement requires regulatory approval from the FTC and DOJ.
  • Axsome continues to face pending patent litigation over SUNOSI with another unnamed party.

The big picture

The settlement extends Axsome's market exclusivity for SUNOSI, a key product in its CNS portfolio, by nearly two decades. This strategic move aligns with broader industry trends of biopharmaceutical companies aggressively defending patent lifelines amid increasing generic competition. The deal underscores the critical role of intellectual property in sustaining revenue streams for specialized CNS therapies.

What we're watching

Patent Defense
Whether Axsome can successfully resolve remaining SUNOSI litigation to maintain market exclusivity.
Regulatory Timing
The pace at which the FTC and DOJ review the settlement agreement.
Market Exclusivity
How the extended patent protection impacts SUNOSI's commercial potential and competitive landscape.